Direct tissue-sensing reprograms TLR4+ Tfh-like cells inflammatory profile in the joints of rheumatoid arthritis patients by Amaral-Silva, Daniela et al.
ARTICLE
Direct tissue-sensing reprograms TLR4+ Tfh-like
cells inflammatory profile in the joints of
rheumatoid arthritis patients
Daniela Amaral-Silva 1,2, Rute Gonçalves1,2, Rita C. Torrão1,2, Rita Torres2,3,4, Sandra Falcão2,3,4,
Maria João Gonçalves3, Maria Paula Araújo3, Maria José Martins3, Carina Lopes3, Agna Neto2,3,4, José Marona3,
Tiago Costa3, Walter Castelão3, Ana Bento Silva 3, Inês Silva3, Maria Helena Lourenço3, Margarida Mateus3,
Nuno Pina Gonçalves2,3,4, Santiago Manica2,3,4, Manuela Costa3, Fernando M. Pimentel-Santos2,3,4,
Ana Filipa Mourão2,3,4, Jaime C. Branco3,4,5 & Helena Soares 1,2,6✉
CD4+ T cells mediate rheumatoid arthritis (RA) pathogenesis through both antibody-
dependent and independent mechanisms. It remains unclear how synovial microenvironment
impinges on CD4+ T cells pathogenic functions. Here, we identified a TLR4+ follicular helper
T (Tfh) cell-like population present in the blood and expanded in synovial fluid. TLR4+ T cells
possess a two-pronged pathogenic activity whereby direct TLR4+ engagement by endo-
genous ligands in the arthritic joint reprograms them from an IL-21 response, known to
sponsor antibody production towards an IL-17 inflammatory program recognized to fuel
tissue damage. Ex vivo, synovial fluid TLR4+ T cells produced IL-17, but not IL-21. Blocking
TLR4 signaling with a specific inhibitor impaired IL-17 production in response to synovial fluid
recognition. Mechanistically, we unveiled that T-cell HLA-DR regulates their TLR4 expres-
sion. TLR4+ T cells appear to uniquely reconcile an ability to promote systemic antibody
production with a local synovial driven tissue damage program.
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In rheumatoid arthritis (RA) combined immune and jointtissue dysregulation synergize in propagating chronic inflam-mation and articular destruction. CD4+ T cells have been
strongly implicated in RA pathogenesis through both antibody-
dependent and independent mechanisms1,2. It remains unclear,
however, which CD4+ T-cell population drives RA and how the
joint microenvironment impinges on their pathogenic functions.
Unveiling CD4+ T-cell pathogenic phenotype and its crosstalk
with the arthritic joint environment would benefit diagnosis,
patient stratification and could contribute to the design of better
drugs that could effectively induce remission.
Effector functions sponsored by CD4 T cells in the joints
constitute an active field of research. Circulating CXCR5+ and/or
PD1+CXCR5+ Tfh cell populations have been correlated with B
cell expansion and increased disease activity3–5. Notwithstanding,
CD4+ T-cell-mediated antibody-independent mechanisms are at
play in RA pathogenesis. Namely, IL-17 production by CD4+
T cells has been implicated in bone erosions6,7 and cartilage
damage8–10, with its neutralization reducing disease activity11 and
curtailing cartilage and bone damage6. IL-17 production is
regulated locally at the affected joint12, requiring both propitious
tissue environment and cell-cell interactions, making it challen-
ging to characterize IL-17 producing CD4+ T cells in RA.
T-cell effector programs are profoundly shaped by the local
tissue microenvironments where antigen recognition occurs13.
RA joints are enriched in endogenous pro-inflammatory mole-
cules and in pathogen recognition receptors that recognize them,
namely Toll-Like Receptors (TLRs). Polymorphisms in TLR4
have been associated with increased RA susceptibility in
humans14 and mice with TLR4 impairments are protected from
experimental arthritis15–17. In addition, TLR4 and its endogenous
ligands are elevated in the synovial fluid and correlate with dis-
ease progression16–20. Even though predominantly expressed on
innate immune cells, TLR4 has been found at low levels in acti-
vated human and mice CD4 T cells21,22. Curiously, TLR4
expression on T cells has been ascribed to both facilitate and
inhibit chronic inflammation23,24, with its role varying according
to tissue affected. It remains to be elucidated if TLR4 expression is
enriched in CD4+ T cells of RA patients and whether the joint
microenvironment engages TLRs directly on CD4+ T cells
imprinting dysregulated inflammation and possibly diversifying
their pathological function.
The strongest genetic association in RA is with HLA-DR
alleles25. HLA-DR is constitutively expressed by antigen-
presenting cells (APCs), whereupon cognate interaction with
the TCR, drives CD4+ T-cell activation26. Even though HLA-DR
has been used as a marker of activated T cells for more than 40
years27,28, whether or not HLA-DR expression plays a functional
role on activated T cells has remained elusive.
By analyzing freshly obtained synovial fluid and blood from
100 RA patients, we identified a TLR4+ Tfh-like cell population
present in blood and expanded in the synovial fluid. Our data
unveil that direct TLR4 stimulation functions as a sensor for
tissue-damage cues, allowing to spatially tailor the pathological
response elicited. Targeting the bidirectional communication
between T cells and the synovium microenvironment might be
critical to restore joint homeostasis and induce RA remission.
Results
A circulating TLR4+CD4+ T-cell population is expanded in
the synovial fluid of RA patients. TLR4 is a robust tissue-damage
sensor implicated in RA initiation and progression18–20,29,30.
Previous studies focused on TLR4 expression by innate immune
cells and synoviocytes19,20,30. Here, we investigated TLR4 expres-
sion by CD4+ T cells in fresh synovial fluid from 12 RA patients
(Supplementary Data 1). Confirming our hypothesis, TLR4 was
indeed expressed by ~25% of synovial CD4+ T cells (Fig. 1a).
When compared to TLR4− T cells, TLR4+ T cells, displayed a
bigger relative size (FSC-A) and complexity (SSC-A) (Fig. 1b, c).
Next, we assessed whether synovial fluid TLR4+ T cells would have
a circulating counterpart by examining freshly obtained peripheral
blood of 100 RA patients. To ensure that we would be inclusive of
CD4+ T cells with higher FSC-A/SSC-A, we gated first on
CD3highCD4high T cells (Fig. 1d). We could detect two CD4+
T-cell populations with distinct relative sizes and complexities.
Through doublet analysis, we observed that these CD4+ T-cell
populations distribute along two distinct diagonals, suggesting that
they are two distinct populations. As determined for synovial
TLR4+ T cells (Fig. 1a), TLR4 expression clustered on FSC-
AhighSSC-AhighCD4+ T cells (Fig. 1d–f). Circulating TLR4+ T cells
frequency (Fig. 1d) ranged between 0.02% and 28.7% (mean 5.89%;
mode 1.27%). Donor-matched analysis revealed that TLR4+ T cells
were enriched in the synovial fluid (Fig. 1g, h) and correlated with
their circulating counterparts (Fig. 1i).
We reasoned that the increase in FSC-A/SSC-A values by
synovial fluid and circulating TLR4+ T cells could reverberate
their increased activation state. We stained for T-cell activation
markers HLA-DR and PD-1. t-SNE analysis showed that PD-1 is
expressed by various T-cell populations, including TLR4+ T cells
while HLA-DR is selectively expressed by TLR4+ T cells (Fig. 1j).
To formally exclude the possibility that bigger size of TLR4+
T cells was owing to cell aggregates, we used HLA-DR as a proxy
marker for TLR4+ T cells and sorted HLA-DR+ and HLA-DR−
CD4+ T cells by flow cytometry (Supplementary Fig. 1), labeled
sorted cells for CD3 and TLR4 and analyzed them by confocal
microscopy (Fig. 1k). Only, HLA-DR+ T cells displayed TLR4 at
the cell membrane, where it colocalized with CD3. As FSC-A only
provides a relative measure of cell size, we calculated the 3D
volume and measured the larger width of both TLR4− and
TLR4+ T cells, and found TLR4+ T cells to be bigger and wider
than TLR4− T cells (Fig. 1k–m). We observed that TLR4+ T cells
exhibited membrane projections and alterations in their cell
shape. To quantify the latter, we calculated the roundness
coefficient, where a roundness index of 1 characterizes perfectly
round cells, with values <1 depicting a departure from it26.
TLR4+ T cells roundness index was ~0.8 (Fig. 1n).
TLR4 expression has been reported on senescent T cells from
spondylarthritis patients31. To exclude that the cells we identified
are non-replicative senescent cells, we labeled them for the
proliferation marker Ki-67. We found that ~75% of TLR4+
T cells were undergoing a cell cycle and ~95% upregulated the
activation marker CD38 (Fig. 2a–e). Upregulation of HLA-DR,
CD38, and Ki-67 by TLR4+ T cells supports their chronic
activation, rather than a senescent state.
Collectively, we have identified a previously uncharacterized
TLR4+ T-cell population in RA patients. TLR4+ T cells are
activated, bigger, highly proliferative, and expanded in the
synovial fluid, suggesting a role for these cells as drivers in RA
pathology.
TCR and CD28 stimulation leads to TLR4 upregulation. To
further characterize this TLR4+ T-cell subset, we checked for CD14
co-expression. CD14 was co-expressed by SSC-Ahigh T cells (Fig. 3a).
Our microscopy data (Fig. 1k) had shown that TLR4 was indeed
expressed by activated HLA-DR+ T cells, raising the possibility that
acquisition of innate immune receptors was a consequence of T-cell
activation status. To check this hypothesis, we FACS-purified CD4+
T cells resorting to a restrictive lymphocyte gate and by excluding
CD14+ cells (Supplementary Fig. 2a). We then stimulated these
CD14−CD3+CD4+SSClowFSClow T cells through the TCR and
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Fig. 1 RA patients display a circulating TLR4+ T-cell population that is expanded in the synovial fluid. a Gating strategy and cumulative frequency of
CD3+CD4+TLR4+ cells in freshly obtained synovial fluid (n= 12 RA patients). b Representative histogram and cumulative plot of relative cell size (FSC-A)
in TLR4− (gray) and TLR4+ (red) synovial fluid T cells (n= 12 RA patients). c Representative histogram and cumulative plot of relative cell complexity
(SSC-A) of TLR4− (gray) and TLR4+ (red) synovial fluid T cells (n= 12 RA patients). d Gating strategy and cumulative frequency of CD3+CD4+TLR4+
cells in freshly obtained peripheral blood (n= 100 RA patients). e Representative histogram and cumulative plot of relative cell size (FSC-A) in TLR4−
(gray) and TLR4+ (red) peripheral blood T cells (n= 100 RA patients). f Representative histogram and cumulative plot of relative cell complexity (SSC-A)
of TLR4− (gray) and TLR4+ (red) peripheral blood T cells (n= 100 RA patients). g Donor-matched analysis of the frequency of TLR4 expression by
CD3+CD4+ T cells in peripheral blood (closed circles; PB) and in synovial fluid (open circles; SF) (n= 12 RA patients). h Donor-matched analysis of the
MFI of TLR4 expression by CD3+CD4+ T cells in peripheral blood (closed circles; PB) and in synovial fluid (open circles; SF) (n= 11 RA patients).
i Correlation between the frequency of CD3+CD4+ TLR4+ T cells in the blood (PB) and in synovial fluid (SF) (n= 12 RA patients). j t-SNE plots of
peripheral blood total CD4+ T cells. The color indicates cell expression levels of labeled markers (TLR4, HLA-DR, and PD-1). Circle demarks TLR4+ cells
(n= 26 RA patients). k–n Confocal microscopy of FACS-purified HLA-DR− and HLA-DR+ CD4+ T cells. k Cells were surface labeled for CD3 and TLR4,
stained for DAPI, and analyzed by 3D confocal microscopy. Bar, 5 μm. l Cumulative graphs of 3D volume (n= 76 HLA-DR−CD4+ T cells; n= 47 HLA-DR
+CD4+ T cells);m larger diameter (n= 76 HLA-DR−CD4+ T cells; n= 47 HLA-DR+CD4+ T cells), and n roundness index (n= 75 HLA-DR−CD4+ T cells;
n= 44 HLA-DR+CD4+ T cells). Data are presented as mean ± SD, for parametric statistical tests, or median ± IQR, for non-parametric statistical tests.
Sample normality distribution was tested by using D’Agostino & Pearson normality test. P values ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were
determined by (b, c, g) Paired t test; (e, f, h) Wilcoxon matched-pairs rank test; (i) Pearson Correlation and (l–n) Mann–Whitney test. Effect size measures
+++high, ++medium, +small were determined by (b, c, g) d – Cohen’s d; (e, f, h, l–n) r – correlation coefficient r, and (i) rp – Pearson’s correlation
coefficient.
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CD28. Sorted CD4+ T cells did not express CD14 (Supplementary
Fig. 2b). Nonetheless, as soon as 1 day after TCR and
CD28 stimulation CD4+ T cells from RA patients gained CD14
expression, which was further enriched by day 5 (Fig. 3b). To
determine whether this TLR4 upregulation was a general feature of
activated T cells, we sorted CD3+CD4+ T cells from healthy donors
(HD; Supplementary Fig. 3c, d, Supplementary Table 1) and stimu-
lated them through TCR and CD28 for 5, 6 days. Polyclonal T-cell
activation led to a homogeneous upregulation of TLR4 in HD.
However, its levels were below the detection limits of FACS and
could only be observed by microscopy (Fig. 3c, d). TLR4 was func-
tional in T cells from HD, as the addition of LPS to the culture led to
an increase in T-cell size (Fig. 3e), survival (Fig. 3f), and proliferation
(Fig. 3g, h).
Altogether, our data suggest that TLR4 upregulation is
subsequent to sustained TCR and CD28 activation and is not a
unique feature of T cells from RA patients. Nonetheless, RA
TLR4+ T cells distinguish themselves by their high levels of TLR4
expression.
TLR4+ T-cell population correlates with anti-CCP antibody
titers. Next, we pursued the relation between TLR4+ T cells and
RA demographics, disease presentation, and treatment. TLR4+
T-cell frequency was not affected by age nor sex (Fig. 4a, b). RA
has two clinical presentations, seropositive RA in which anti-
bodies to either rheumatoid factor (RF) or to citrullinated (CCP)
proteins are present and seronegative RA in which such anti-
bodies are absent. TLR4+ T cells were present in both ser-
opositive and seronegative patients (Fig. 4c–e), with TLR4+ T-cell
frequency correlating with anti-CCP antibody titers (Fig. 4f). The
majority of patients in our cohort were either in clinical remission
(61.7%) or presented low (16.0%) to moderate (21.0%) disease
activity. Reflecting the high prevalence of patients with the
controlled disease, we did not detect any correlation between
disease activity scores DAS28 ESR (Fig. 4g) and DAS28 CRP
(Fig. 4h) and TLR4+ T cells frequency. Likewise, there was no
detectable difference in TLR4+ T-cell frequency among treat-
ments (Fig. 4i–k). When analyzed by individual drug use meth-
otrexate (Fig. 4l) and leflunomide (Fig. 4m) exhibited a trend for
slightly better and worse outcomes, respectively (Fig. 4l–p). At
last, DMARD treatment duration does not impact TLR4+ T-cell
frequency (Fig. 4q).
In summary, TLR4+ T cells persist in patients with controlled
RA, regardless of the treatment regimen, and correlate with anti-
CCP antibody titers.
HLA-DR drives TLR4 surface expression. The strongest genetic
association for developing RA is carried by HLA-DR alleles25.
Even though HLA-DR has been used as a marker of T-cell acti-
vation for >40 years, its functional role has remained elusive.
Intrigued by the strong co-expression between HLA-DR and
TLR4 (Figs. 1j, 5a), we analyzed the frequency of TLR4 expression
by HLA-DR+CD4+ T cells (Fig. 5b) and reciprocally, the fre-
quency of HLA-DR expression by TLR4+CD4+ T cells (Fig. 5c).
Although 87.3% of HLA-DR+CD4+ T cells co-expressed TLR4,
99.4% of TLR4+CD4+ T cells co-expressed HLA-DR. When
looking at their cellular abundance, higher expression of HLA-DR
was accompanied by greater TLR4 expression (Fig. 5d). Taken
together, the above data suggested that there might be a link
between HLA-DR and TLR4 expression.
We posited that HLA-DR could control TLR4 expression on
T cells. To address this possibility, we purified circulating CD4+
T cells with purity >99% (Supplementary Fig. 3a, b) and
incubated them overnight with an anti-HLA-DR-blocking anti-
























































































Fig. 2 TLR4+ T cells display an activated and proliferative phenotype. a t-SNE plots of peripheral blood total CD3+CD4+ T cells. The color indicates cell
expression levels of labeled markers (TLR4, Ki-67, and CD38). Circle demarks TLR4+ cells (n= 6 RA patients). b, c Representative dot plots and
cumulative graphs of the b frequency and c ΔMFI of Ki-67 expression by TLR4− and TLR4+ peripheral blood T cells (n= 13 RA patients).
d, e Representative dot plots and cumulative graphs of the d frequency and e ΔMFI of CD38 expression by TLR4− and TLR4+ peripheral blood T cells
(n= 13 RA patients). ΔMFI was calculated to correct for the distinct autofluorescence of the TLR4− and TLR4+ T-cell populations. ΔMFI was calculated by
subtracting the fluorescence intensity minus one (FMO) from median fluorescence intensity (MFI) for each given marker. Data are presented as
mean ± SD, for parametric statistical tests, or median ± IQR, for non-parametric statistical tests. Sample normality distribution was tested by using
D’Agostino & Pearson normality test. P values ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were determined by (b) Paired t test and (c–e) Wilcoxon
matched-pairs rank test. Effect size measures +++high, ++medium, +small were determined by (b) d – Cohen’s d and (c–e) r – correlation coefficient r.
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Gated on CD3+CD4+ T cells RA pre-sorting
13.7%
Fig. 3 TCR and CD28 stimulation lead to CD14 and TLR4 upregulation in RA patients and in healthy donors. a Representative dot plot and cumulative
graph of the frequency of CD14 expression in CD3+CD4+ T cells of peripheral blood of RA patients (n= 6 RA patients). b Representative dot plot and
cumulative graph of CD14 expression by FACS-purified CD14−CD3+CD4+SSClowFSClow T cells from RA patients after 1 and 5 days with and without αCD3
and αCD28 stimulation (n= 4 RA patients). c–d Confocal microscopy of FACS-purified CD3+CD4+SSClowFSClow T cells from healthy donors (HD) that
were either left unstimulated (unst) or were stimulated with αTCR and αCD28 for 5 days in the presence or absence of LPS. c Cells were surface labeled for
CD45 and TLR4 and analyzed by 3D confocal microscopy. Bar, 5 μm. d Cumulative graphs of 3D TLR4 fluorescence (n= 143 cells from four different HD,
n= 43 cells unstimulated, n= 40 cells TCR CD28 and n= 50 cells TCR CD28 LPS conditions). e Representative histogram and cumulative plot of FSC MFI
of CD4+ T cells from HD stimulated for 5 days with αTCR and αCD28 in the presence or absence of LPS (n= 30 HD, 53 independent experiments).
f Representative dot plots and cumulative graph of the frequency of viable cells CD4+ T from HD stimulated for 5 days with αTCR and αCD28 in the
presence or absence of LPS and labeled with cell viability dye (n= 30 HD, 39 independent experiments). g Representative histogram and cumulative plot of
cell trace MFI of CD4+ T cells from HD stimulated for 5 days with αTCR and αCD28 in the presence or absence of LPS (n= 5 HD). h Representative dot
plots and cumulative graph of proliferative CD4+ T cells from HD stimulated for 5 days with αTCR and αCD28 in the presence or presence or absence of
LPS (n= 5 HD). Data are presented as mean ± SD, for parametric statistical tests, or median ± IQR, for non-parametric statistical tests. Sample normality
distribution was tested by using D’Agostino & Pearson normality test (n > 6) or Shapiro–Wilk normality test (n≤ 6). P values ****p≤ 0.0001, ***p≤ 0.001,
**p≤ 0.01, *p≤ 0.05 were determined by (b) Ratio-paired t test; (d) Kruskal–Wallis test with posttest Dunn’s multiple comparisons; the p values are
adjusted for multiple comparisons; (e, g, h) Wilcoxon matched-pairs rank test and (f) Paired t test. Effect size measures +++high, ++medium, +small were
determined by (b, f) d – Cohen’s d; (d) η2 – eta-squared and (e, g, h) r – correlation coefficient r.
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decrease in TLR4 surface expression (Fig. 5e), indicating that
HLA-DR regulates TLR4 expression.
Our data identify, for the first time, a functional role for HLA-
DR on CD4+ T cells through the regulation of TLR4 expression
and suggests a novel mechanism by which HLA-DR might drive
RA disease susceptibility.
TLR4+ T cells share features of Tfh cells. Tfh-like T cells have
been implicated in RA and other chronic inflammatory diseases
owing to their capability to induce antibody production5,32,33. We
checked whether TLR4+ T cells would share Tfh features, namely
high expression of chemokine receptor CXCR5 and of the co-
receptors PD-1 and ICOS. The receptor gating for each T-cell
population was established by their individual fluorescence minus
one (FMO) value (Supplementary Fig. 4). Even though CXCR5
(Fig. 6a–c) and PD-1 (Fig. 6a, d, e) could be detected in both
TLR4− and TLR4+ T-cell populations, they were enriched in
TLR4+ T cells with a co-expression of ~60% (Fig. 6f). Curiously,
ICOS was more expressed in TLR4− than in TLR4+ T cells
(Fig. 6a, g, h). Nonetheless, in TLR4+ T cells co-expression of
ICOS and CXCR5 (Fig. 6i) and ICOS and PD-1 (Fig. 6j) was
enriched. The fact that TLR4+ T cells are enriched in CXCR5 and
PD-1 suggests that they might consist of a circulating Tfh-like
population34,35. To characterize this further, we explored whether
the enrichment in TLR4+ T cells could reflect the frequency of
circulating Tfh cells. TLR4+ T-cell frequency positively correlated
with the frequency of CXCR5+ (Fig. 6k) and PD-1+ (Fig. 6l)
circulating CD4+ T cells.
Altogether, these data indicate that TLR4+ T cells display Tfh-
like features.
TLR4+ T cells display migratory phenotype to inflamed tissues.
TLR4+ T-cell enrichment in synovial fluid (Fig. 1g, h) cannot be
fully explained by their CXCR5 expression. Therefore, we checked
for the expression of chemokine receptors CCR2 and CCR6 that
regulate T-cell migration to inflamed tissues and whose ligands are
abundantly present in arthritic synovium and have been implicated
in the disease36,37. Both CCR2 and CCR6 were upregulated by
TLR4+ T cells (Fig. 7a–e). CCR2 and CCR6 are expressed by ~100%
and ~30% of TLR4+ T cells, respectively (Fig. 7b–e). Although
CCR2 guides a broad range of immune cells into sites of inflam-
mation, CCR6 is associated with the recruitment of IL-17-producing
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Fig. 4 The frequency of TLR4+ T correlates with anti-CCP antibody titers and age, independently of treatment. a Frequency of TLR4+ T cells
disaggregated by age (n= 101 RA patients; ≤65 years n= 64; >65 years n= 37). b Frequency of TLR4+ T cells disaggregated by sex (n= 101 RA patients;
female n= 86; male n= 15). c Frequency of TLR4+ T cells disaggregated by factor rheumatoid (RF) status (n= 84 RA patients; RF+ n= 65; RF− n= 19).
d Correlation between factor rheumatoid titers and frequency of TLR4+ T cells in rheumatoid factor positive patients (n= 65 RF+ RA patients).
e Frequency of TLR4+ T cells disaggregated by factor anti-CCP antibody status (n= 96 RA patients; CCP+ n= 71; CCP− n= 25). f Correlation between
factor anti-CCP antibody titers and frequency of TLR4+ T cells in CCP-positive patients (n= 71 CCP+ RA patients). g Correlation between frequency of
TLR4+ T cells and DAS28 ESR score (n= 81 RA patients). h Correlation between frequency of TLR4+ T cells and DAS28 CRP score (n= 81 RA patients).
i Frequency of TLR4+ T cells disaggregated by treatment family (N/S- NSAID and/or corticosteroids n= 8; D- DMARDs n= 80; bD- biological DMARDs
n= 13 RA patients). j–p Frequency of TLR4+ T cells segregated by medication usage (n= 101 RA patients). j NSAIDs, k corticosteroids, l methotrexate,
m leflunomide, n hydroxychloroquine, o Sulfasalazine, p biological DMARDs. q Correlation between DMARD treatment duration and frequency of TLR4+
T cells (n= 89 RA patients). Data are presented as mean ± SD, for parametric statistical tests, or median ± IQR, for non-parametric statistical tests. Sample
normality distribution was tested by using D’Agostino & Pearson normality test (n > 6) or Shapiro–Wilk normality test (n≤ 6). P values ****p≤ 0.0001,
***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were determined by (a–c, e, j–p) Mann–Whitney test; (d, f–h, q) Spearman Correlation and (i) Kruskal–Wallis test.
Effect size measures +++high, ++medium, +small were determined by (a–c, e, j–p) r – correlation coefficient r; (d, f–h, q) rs – Spearman’s correlation
coefficient and (i) η2 – eta-squared.
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T cells to inflamed joints38, suggesting an IL-17 inflammatory
component to TLR4+ T-cell synovial recruitment. To address this
possibility, we checked whether TLR4+ T cells upregulate receptors
for pro-inflammatory cytokines that are overexpressed in inflamed
synovium (IL-1, IL-6, and IL-17) and which have been implicated in
IL-17 production38–40 (Figs. 7a, 8a, b). IL-1R was selectively upre-
gulated by TLR4+ T cells (Figs. 7a, 8c, d). As expected from IL-6
pleiotropic role, IL-6R was similarly expressed by both TLR4+ and
TLR4− T-cell populations (Fig. 8a, e, f). Finally, IL-17R was greatly
enriched in TLR4+ T cells (Fig. 8b, g, h). In addition, IL-2 alpha (IL-
2Rα), which regulates cell size was upregulated by TLR4+ T cells
(Fig. 6b, i, j).
Taken together, TLR4+ T cells emerge as a Tfh-like cell
population with a preferential tropism for inflamed tissues and
increased capability to respond to IL-17-promoting stimuli IL-1
and IL-17.
TLR4 engagement reprograms TLR4+ T-cell inflammatory
profile. In experimental autoimmune encephalitis, TLR4
engagement on CD4+ T cells has been reported to function as a
co-receptor boosting T-cell survival and proliferation without
affecting the amount of the cytokines produced24. Whether or not
direct TLR4 engagement on human CD4+ T cells modulates or
alters CD4+ T-cell inflammatory profile has remained
unanswered.
To unveil the contribution of direct TLR4 engagement on
T-cell inflammatory profile, we purified circulating CD4+ T cells
(Supplementary Fig. 3b; purity >99%) and stimulated them with
TLR4 ligand LPS in the presence or absence of TCR and ICOS
engagement. We looked at antibodies (IL-2132 and IL-1041), or
and joint damage (IL-1042, IL-178,12,43,44, and TNF-α45) inducing
cytokines. Circulating TLR4+ T cells produced IL-10, IL-21, and
IL-17 in unstimulated conditions, supporting their ongoing
activation state. In vitro, IL-21 production required TCR and
ICOS stimulation and was completely non-responsive to LPS
(Fig. 9a, b). In contrast, LPS, in combination with TCR and ICOS
stimulation, boosted IL-10, IL-17, and TNF-α production
(Fig. 9c–h). Moreover, LPS alone was sufficient to drive the
production of IL-10 and trended to increase IL-17 and TNF-α
production (Fig. 9c, g).
Altogether these data indicate that direct TLR4 stimulation
goes beyond functioning as a co-receptor boosting TCR-driven
response and suggest that TLR4 engagement by LPS might
reprogram TLR4+ T cells from an IL-21 driven pro-antibody to
an inflammatory program fueling joint damage
Direct recognition of TLR4 ligands present in synovial fluid
drives IL-17 production, independently of antigen recognition.
Increased expression of endogenous TLR4 ligands has been
observed in the blood and synovial fluid of RA patients, with a
role in arthritis being suggested in mice models46–49. Of all the
proposed endogenous TLR4 ligands, tenascin-C (TNC) is the one
more thoroughly analyzed, including the molecular identification
of its binding sites on TLR450. We quantified TNC in synovial
fluid of RA patients (Fig. 10a–c). Synovial TNC levels are inde-
pendent of the duration of DMARD treatment (Fig. 10a).
Moreover, TLR4+ T cells are enriched in synovial fluids with
higher TNC levels (Fig. 10b, c), opening the possibility that TNC
might play a role in the enrichment of TLR4+ T cells in the
synovial fluid. As circulating TLR4+ T cells produced IL-17 and
IL-10 prior to in vitro restimulation (Fig. 9), we wondered whe-
ther this basal cytokine production was due to the ongoing
engagement of TLR4. To address this possibility, we treated cir-
culating TLR4+ T cells with either medium or with the
TLR4 signaling inhibitor CLI-095. Blocking TLR4 signaling
hampered both IL-17 and IL-10 production (Supplementary
Fig. 5a–d). To further explore the role of direct TLR4 engagement
by synovial components, we stimulated sorted CD3highCD4high
T cells with either TNC (Supplementary Fig. 5h, i) or with cell-
depleted synovial fluid in the presence or absence of
TLR4 signaling inhibitor (Fig. 10d–g). Whereas stimulation with
TNC led to the production of IL-10 and TNF-α, but not of IL-17,
a
medium anti-HLA-DR
Gated on CD4+ T cells Gated on HLA-DR+ T cells Gated on TLR4+ T cells

























































































































Fig. 5 Blocking HLA-DR abrogates TLR4 surface expression in T cells. a Representative plot and cumulative graph (n= 99 RA patients) of the frequency
of HLA-DR+TLR4+ T cells. b Representative plots and cumulative graph (n= 99 RA patients) of the frequency of TLR4 expression by HLA-DR+ T cells.
c Representative plots and cumulative graph (n= 99 RA patients) of the frequency of HLA-DR expression by TLR4+ T cells. d Correlation between HLA-
DR and TLR4 MFIs in TLR4+ T cells (n= 99 RA patients). e Representative plots and cumulative graph (n= 17 RA patients) of the frequency of TLR4+
T cells after incubating FACS-purified CD4+ T cells with a blocking antibody to HLA-DR for 18 hours. Data are presented as mean ± SD, for parametric
statistical tests, or median ± IQR, for non-parametric statistical tests. Sample normality distribution was tested by using D’Agostino & Pearson normality
test. P values ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were determined by (d) Spearman correlation and (e) Wilcoxon matched-pairs rank test.
Effect size measures +++high, ++medium, +small were determined by (d) rs – Spearman’s correlation coefficient and (e) r – correlation coefficient r.
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IL-21, or IFN-γ (Supplementary Fig 5h–I), stimulation with-
synovial fluid-induced IL-17 in all the 5 donors analyzed
with increases ranging between 1.5- and 4.7-fold (Fig. 10d). In
comparison with LPS stimulation (Fig. 9), cell-depleted synovial
fluid was less prone to induce IL-10 and TNF-α production with
only three out of five donors responding to stimulation (Fig. 10e,
f) and uncapable of inducing IL-21 production (Fig. 10g).
Notably, increased IL-17 production appears to be mediated
by direct TLR4 engagement, as the addition of
TLR4 specific signaling inhibitor CLI-095 at least impairs (two
a
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Fig. 6 TLR4+ T cells have features of Tfh-like cells. a t-SNE plots of peripheral blood total CD4+ T cells. The color indicates cell expression levels of
labeled markers (TLR4, CXCR5, ICOS, and PD-1). Circle demarks TLR4+ cells (n= 6 RA patients). b, c Representative plots and cumulative analysis (n= 13
RA patients) of CXCR5 b frequency and c ΔMFI in TLR4+ (red) versus TLR4− (gray) T cells. d, e Representative plots and cumulative analysis (n= 13 RA
patients) of PD-1. d frequency and e ΔMFI in TLR4+ (red) versus TLR4− T cells (gray). f Representative plots and cumulative analysis (n= 13 RA patients)
of the frequency of CXCR5 and PD-1 co-expression TLR4+ (red) versus TLR4− (gray) T cells. g, h Representative plots and cumulative analysis (n= 13 RA
patients) of ICOS g frequency and h ΔMFI in TLR4+ (red) versus TLR4− (gray) T cells. i Representative plots and cumulative analysis (n= 13 RA patients)
of the frequency of CXCR5 and ICOS co-expression in TLR4+ (red) versus TLR4− (gray) T cells. j Representative plots and cumulative analysis (n= 13 RA
patients) of the frequency of ICOS and PD-1 co-expression TLR4+ (red) versus TLR4− (gray) T cells. k Correlation between the frequency of
TLR4+CXCR5+ T cells and TLR4−CXCR5+ cells (n= 13 RA patients). l Correlation between the frequency of TLR4+PD1+ T cells and TLR4−PD1+ cells
(n= 13 RA patients). ΔMFI was calculated to correct for the distinct autofluorescence of the TLR4− and TLR4+ T-cell populations. ΔMFI was calculated by
subtracting the fluorescence intensity minus one (FMO) from median fluorescence intensity (MFI) for each given marker. Data are presented as
mean ± SD, for parametric statistical tests, or median ± IQR, for non-parametric statistical tests. Sample normality distribution was tested by using
D’Agostino & Pearson normality test. P values ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were determined by (b–f, h–j) Wilcoxon matched-pairs
rank test; (g) Paired t test and (k, l) Spearman Correlation. Effect size measures +++high, ++medium, +small were determined by (b–f, h–j) r – correlation
coefficient r; (g) d − Cohen’s d; and (k, l) rs – Spearman’s correlation coefficient.
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out of five donors), and in most cases (three out of five donors)
completely abrogates, IL-17 production (Fig. 10d). In contrast to
LPS (Fig. 9), direct TLR4 engagement by endogenous synovial
ligands boosted IL-17 production independently of TCR cross-
linking (Fig. 10d).
To scope the pathophysiological role that endogenous TLR4
ligands might exert on the inflammatory program of synovial
TLR4+ T cells, we compared the cytokine profile of circulating
and synovial TLR4+ T cells ex vivo. In this approach, freshly
obtained and paired blood and synovial fluid mononuclear cells
were immediately labeled for IL-17, IL-10, TNF-α, and IL-21
(Fig. 10h–k). In four out of five donors, ex vivo IL-17 production
by TLR4+ T cells tended to be higher in the synovial fluid than in
the blood (Fig. 10h). Curiously, IL-10 production appears to be
less compartmentalized with only one donor (out of five)
displaying higher IL-10 production by synovial TLR4+ T cells
(Fig. 10i). At last, in our sampling TNF-α and IL-21 production
was hard to detect in either blood or synovial TLR4+ T cells
ex vivo (Fig. 10j, k).
Altogether, our results indicate that direct TLR4 engagement
by endogenous ligands in synovial fluid favors the production of
IL-17. In contrast with LPS, endogenous synovial TLR4 ligands
reprogram TLR4+ T cells inflammatory profile independently
of TCR engagement. Lastly, cytokine production by synovial
TLR4+ T cells suggests a major role for IL-17 in their pathogenic
function.
Discussion
RA is a chronic inflammatory disease where CD4+ T cells and
joint tissue dysregulation synergize in propagating chronic
inflammation and articular destruction. Treatment of RA remains
challenging as the identity of CD4+ T-cell population driving RA
and the mechanism by which joint microenvironment impinges
dysregulated T-cell activation remain elusive. Here, we identified
a circulating TLR4+ T-cell population that is enriched in synovial
fluid of RA patients. TLR4+ T cells are uniquely attuned to
respond distinctively to different contextual clues by reconciling
an ability to potentially promote systemic antibody production
with an in situ synovial driven tissue-damage program. Our
results highlight the contribution of spatial compartmentalization
to T-cell-driven pathogenicity and the role of tissue environment
in tailoring site-specific T-cell responses.
Tfh-like cell populations have been described in several chronic
inflammatory diseases including rheumatoid arthritis2, lupus
nephritis51, and systemic sclerosis45. In addition, in RA, a
population of IL-21-producing peripheral helper T (Tph) cells
has been identified32. Here, we have identified a previously
unknown Tfh-like population. TLR4+ T cells were enriched in
Tfh cell markers, CXCR5, and PD-134,35,52, and their frequency
in circulation correlated with anti-CCP antibody levels. These sets
of Tfh/Tph cells might indeed account for distinct T-cell popu-
lations or might represent the same cell population in different
disease stages and/or responses to treatment. Distinctly from the
previous reports2,32,45,51, we analyzed freshly obtained blood and
synovial fluid samples, rather than frozen ones. Fresh samples
facilitate the identification of infrequent T-cell populations and
the detection of certain markers and allow for better detection of
changes in cell size and shape.
Early descriptions of TLR4+ T had similarly reported an
increase in cell size41. Likewise, in vitro and in vivo experiments
show that IL-17-producing cells have a bigger size which has been
associated with increased cytokine secretion in vitro42. As TLR4+
T cells FSC-A values were outside the conventional lymphocyte
gate, we took care to exclude the occurrence of cell aggregates53.
First, our doublet analysis (FSC-W vs FCS-A) into two distinct
diagonals is suggestive of two cell populations rather than
doublets. Second, confocal microscopy of purified CD4+ T cells
(~99% purity) confirmed co-expression of TLR4 and CD3
exclusively by HLA-DR+FSC-Ahigh cells. TLR4 was expressed
uniformly along the cell membrane, excluding the possibility of




















































































Fig. 7 TLR4+ T cells express inflammatory chemokine receptors CCR2 and CXCR6. a t-SNE plots of peripheral blood total CD4+ T cells. The color
indicates cell expression levels of labeled markers (TLR4, CCR2, CCR6, IL-1R). Circle demarks TLR4+ cells (n= 6 RA patients). b, c Representative plots
and cumulative graph (n= 12 RA patients) of CCR2 b frequency and c ΔMFI in TLR4+ (red) and TLR4− (gray) T cells. d, e Representative plots and
cumulative graph (n= 12 RA patients) of CCR6 d frequency and e ΔMFI in TLR4+ (red) and TLR4− (gray) T cells. ΔMFI was calculated to correct for the
distinct autofluorescence of the TLR4− and TLR4+ T-cell populations. ΔMFI was calculated by subtracting the fluorescence intensity minus one (FMO)
from median fluorescence intensity (MFI) for each given marker. Data are presented as mean ± SD, for parametric statistical tests, or median ± IQR, for
non-parametric statistical tests. Sample normality distribution was tested by using D’Agostino & Pearson normality test. P values ****p≤ 0.0001,
***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were determined by (b, e) Wilcoxon matched-pairs rank test and (c, d) Paired t test. Effect size measures +++high,
++medium, +small were determined by (b, e) r – correlation coefficient r and (c, d) d – Cohen’s d.
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interactions with APCs54. The increase in cell size combined with
membrane projections likely underpins the twofold increase in
FSC-A value detected by flow cytometry. An increase in cell size
accompanied by the expression of activation markers CD38 and
HLA-DR further argue that TLR4+ T cells are indeed blasts. To
further characterize whether the acquisition of TLR4 was related
to T-cell activation, we checked if T cells from RA patients could
acquire the TLR4 co-receptor, and often used monocyte marker,
CD14. To this end, we sorted CD14−CD3+CD4+SSClowFSClow
cells and stimulated them for 5 days through TCR and CD28.
T cells from RA patients efficiently acquired CD14 in a TCR
stimulation-dependent manner. Similarly, we sorted CD4+ T cells
from HDs and observed that TCR and CD28 stimulation led to
TLR4 expression, albeit at lower levels than the one observed in
RA patients. Nonetheless, TLR4 in HD T cells was functional and
mediated increased cell size, survival, and proliferative capacity.
Altogether these data support the view that TCR stimulation
drives TLR4 expression in T cells and that in HDs TLR4 levels are
contained, whereas in RA patients this regulatory threshold seems
to be breached. It is tempting to speculate that higher TLR4 levels
might be capable of driving T-cell reprogramming in an antigen
recognition-independent manner, while lower TLR4 levels are
restricted to driving T-cell survival and proliferation.
HLA-DR is class II major histocompatibility molecules (MHC
II) commonly present in APCs, where recognition of foreign-
antigen bearing MHC by their cognate TCR on T cells drives
antigen-specific T-cell activation26,55. HLA-DR haplotypes con-
stitute the strongest genetic association with RA56. So far,
research addressing this genetic association has focused on
identifying the immunodominant peptide presented by HLA-DR
on APCs driving dysregulated T-cell activation in RA patients.
Even though, several CCP candidate peptides can be presented by
HLA-DRB157, the search for immunodominant T-cell epitopes
has so far revealed unfruitful. The observation that HLA-DR is
expressed by activated T cells is longstanding27,28, including a
recent identification of an HLA-DR+ T-cell subset in RA









































































































































































Fig. 8 TLR4+ T cells upregulate receptors for inflammatory chemokine cytokines. a, b t-SNE plots of peripheral blood total CD4+ T cells. The
color indicates cell expression levels of the labeled marker. a TLR4, IL-6R; TLR4, IL-17R, and IL-2Rα. Circle demarks TLR4+ cells (n= 6 RA
patients). c, d Representative plots and cumulative graph (n= 12 RA patients) of IL-1R c frequency and d ΔMFI in TLR4+ (red) and TLR4− (gray) T cells.
e, f Representative plots and cumulative graph (n= 13 RA patients) of IL-6R e frequency and f ΔMFI in TLR4+ (red) and TLR4− (gray) T cells.
g, h Representative plots and cumulative graph (n= 13 RA patients) of IL-17R g frequency and h ΔMFI in TLR4+ (red) and TLR4− (gray) T cells.
i–j Representative plots and cumulative graph (n= 13 RA patients) of IL-2Rα i frequency and j ΔMFI in TLR4+ (red) and TLR4− (gray) T cells. ΔMFI was
calculated to correct for the distinct autofluorescence of the TLR4− and TLR4+ T-cell populations. ΔMFI was calculated by subtracting the fluorescence
intensity minus one (FMO) from median fluorescence intensity (MFI) for each given marker. Data are presented as mean ± SD, for parametric statistical
tests, or median ± IQR, for non-parametric statistical tests. Sample normality distribution was tested by using D’Agostino & Pearson normality test.
P values ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were determined by (c–e, g, i, j) Wilcoxon matched-pairs rank test and (f, h) Paired t test.
Effect size measures +++high, ++medium, +small were determined by (c–e, g, i, j) r – correlation coefficient r and (f, h) d – Cohen’s d.
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We unveiled for the first time a function for HLA-DR on
T cells. By using an anti-HLA-DR-blocking antibody on FACS-
purified CD4+ T cells, we uncovered that HLA-DR regulates
TLR4 surface expression on T cells. Previous works have reported
that HLA-DRB1 might interact with citrullinated calreticulin at
the surface of cells59. It is possible that this is the mechanism
underpinning TLR4 regulation by HLA-DR. However, since we
show that TCR stimulation drives TLR4 and CD14 expression in
CD4+ T cells from HDs and RA patients, we favor the view that
HLA-DR:TCR interactions between neighboring T cells under-
pins TLR4 upregulation. Non-cognate HLA-DR:TCR interactions
between APCs and T cells are known to alter T-cell genetic
profile60,61. Thus, it is possible that T-T-cell interactions through
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expression. Another possibility is that these HLA-DR:TCR
interactions stabilize TLR4 expression at the T-cell plasma
membrane. Further studies will be needed to dissect the
mechanism by which HLA-DR regulates TLR4 expression on
T cells. It is possible that HLA-DR:TCR interactions occur more
frequently in the densely packed joint environment, where
TLR4+ T cells are enriched. Suggesting the enticing possibility
that HLA-DR mediated T:T-cell interactions might sensitize for
joint microenvironment recognition and for a contextually
driven shift of their pathological program. Interestingly, a recent
paper has shown that T:T-cell interactions play a critical role in
driving IL-17 inflammatory responses in conditions of antigen
scarcity62.
TLR4 is a relatively promiscuous immune sensor that recog-
nizes both microbial and endogenous ligands. This is in stark
contrast with the TLR4+ Tfh-like cell population reported here;
TLR4+ T cells were expanded in synovial fluid, and even though
they were enriched for PD-1 they did not exhibit signs of either
exhaustion or senescence, as illustrated by their highly pro-
liferative status and increased ability to produce cytokines in
response to stimulation. In addition to CXCR5, TLR4+ T cells
also expressed the chemokine receptors CCR2 and CCR6
Fig. 9 Direct recognition of LPS by TLR4+ T cells reprograms their cytokine program. FACS-purified CD3highCD4high T cells from freshly obtained
peripheral blood were cultured for 18 hours and stimulated with either α-CD3 and α-ICOS (TCR ICOS); α-CD3, α-ICOS, and LPS (TCR ICOS LPS); LPS alone;
or left unstimulated (unst). a Frequency and b ΔMFI of IL-21 production by TLR4+ T cells (n= 7 RA patients). c Frequency and d ΔMFI of IL-10 production
by TLR4+ T cells (n= 7 RA patients). e Frequency and f ΔMFI of TNF-α production by TLR4+ T cells (n= 5 RA patients). g Frequency and h ΔMFI of IL-17
production by TLR4+ T cells (n= 12 RA patients). ΔMFI was calculated by subtracting the fluorescence intensity minus one (FMO) from median
fluorescence intensity (MFI) for each given marker. Data are presented as median ± IQR and mean (+), for parametric statistical tests, median ± IQR, for
non-parametric statistical tests. Sample normality distribution was tested by using D’Agostino & Pearson normality test (n > 6) or Shapiro–Wilk normality
test (n≤ 6). P values ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were determined by (a, b, d, e–h) Friedman test with posttest Dunn’s multiple
comparisons and (c) Repeated measures ANOVA with posttest Tukey’s multiple comparisons; the p values are adjusted for multiple comparisons. Effect
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Fig. 10 Direct recognition of TLR4 ligands present in synovial fluid drives IL-17 production, independently of antigen recognition. a–c Correlation
between synovial fluid tenascin-C levels and a DMARD duration (n= 6 RA patients), b frequency of circulating (PB) TLR4+ T cells (n= 7 RA patients), and
c frequency of synovial fluid (SF) TLR4+ T cells (n= 7 RA patients). d–g FACS-purified CD3highCD4high T cells from peripheral blood were cultured for
18 hours in the presence of medium (Med), synovial fluid (SF), or TLR4 signaling inhibitor (CLI-095). Frequency of d IL-17, e IL-10, f TNF-α, and g IL-21
production by TLR4+ T cells (n= 5 RA patients). h–k Ex vivo production of h IL-17 (n= 6 RA patients), i IL-10 (n= 5 RA patients), j TNF-α (n= 5 RA
patients) and k IL-21 (n= 5 RA patients) by TLR4+ T cells in freshly obtained peripheral blood (PB) and synovial fluid (SF) donor paired samples. ΔMFI was
calculated by subtracting the fluorescence intensity minus one (FMO) from median fluorescence intensity (MFI) for each given marker. FMOs were
calculated independently for blood and synovial fluid FACS analysis. Data are presented as mean ± SD, for parametric statistical tests, or median ± IQR, for
non-parametric statistical tests. Sample normality distribution was tested by using D’Agostino & Pearson normality test (n > 6) or Shapiro–Wilk normality
test (n≤ 6). P values ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 were determined by (a–c) Pearson correlation; (d, f, g) Friedman test with posttest
Dunn’s multiple comparisons when significant results were obtained and (e) repeated measures ANOVA with posttest Tukey’s multiple comparisons; (h–j)
Paired t test and (k) Wilcoxon matched-pairs rank test; the p values are adjusted for multiple comparisons. Effect size measures +++high, ++medium,
+small were determined by (a–c) rp – Pearson’s correlation coefficient; (d, f, g) W – Kendall’s W; (e) ηp2 – partial eta-squared; (h–j) d – Cohen’s d and (k)
r – correlation coefficient r.
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indicating preferential recruitment to inflamed tissues, which
might account for their enrichment in the affected joints. Inter-
estingly, TLR4 signaling has been reported to augment T-cell
migration and invasiveness63,64, opening the possibility that
direct TLR4 engagement could propel T-cell invasiveness into the
affected joints.
In mice models of autoimmune diseases, TLR4 signaling in
CD4+ T cells has been reported to function both as disease
facilitator24 and protector23. Nonetheless, a role for direct TLR4
engagement in T-cell cytokine profile and function had not been
reported so far. Our data show that while TCR engagement favors
the production of antibody-inducing cytokine IL-21, TLR4
engagement by either LPS or synovial fluid components ensues
IL-17, IL-10, and TNF-α production, cytokine whose role in RA
has been ascribed to promoting joint damage8,12,42–45. Even
though IL-10 is often labeled as an anti-inflammatory cytokine, it
is well established that IL-10 has both immunosuppressive and
stimulatory effects, including cytotoxic activity against tumors65.
In RA, IL-10 has been reported to drive inflammatory arthritis
and joint destruction66. The existence of an antibody-
independent pathogenic function for TLR4+ T cells would
explain why this population is also present in seronegative RA
patients.
Curiously, although TLR4 engagement by LPS functions as a
costimulatory signal boosting TCR signaling, TLR4 ligation by
endogenous TLR4 ligands fuels TLR4+ T-cell inflammatory
program independently of cognate antigen recognition. Distinct
ligands ensuing different TLR4 responses are likely owing to the
fact that TLR4 has multiple binding sites50. In fact, TLR4 ligation
by endogenous ligands TNC and fibronectin is not blocked by an
LPS mimetic, which blocks TLR4 activation by competing with
LPS for TLR4/MD-2 binding19,67. In addition, gene expression
profiles induced by hyaluronan and TNC are significantly dif-
ferent from those induced by LPS19,68,69. Consistent with these
previous reports, we observed that while TNC induced an IL-10
response, endogenous ligands present in synovial fluid favored
IL-17 production. Even though, we cannot formally exclude that
other components present in the synovial fluid might affect T-cell
function, blocking TLR4 in the presence of synovial fluid com-
pletely abrogated (three out of five donors) or at the very least
impaired (two out of five donors) IL-17 production. Thus, we can
conclude that the production of IL-17 induced by the synovial
fluid is specifically mediated by TLR4 on T cells. In view of our
TNC results, it is likely that these TLR4 sponsored effects are
mediated by the combined action of several endogenous TLR4
ligands present in the joints.
Importantly, ex vivo freshly analyzed synovial TLR4+ T cells
seemed to be skewed toward IL-17 production. When compared
with in vitro stimulation with cell-depleted synovial fluid, syno-
vial TLR4+ T cells appear to be poised to produce more IL-17,
less IL-10, and no TNF-α. These differences might be owing to
the fact that to release cells from synovial fluid, it is necessary to
degrade it enzymatically. Hyaluronidase digestion could give rise
to additional TLR4 ligands that could be more adept at inducing
IL-10 and TNF-α in vitro restimulation assays. In particular,
different molecular weight hyaluronic acid fragments are known
to elicit distinct inflammatory profiles70. It is possible that in vivo,
IL-17 is the main cytokine induced by direct engagement of TLR4
on synovial T cells, where it might play a prominent role in
mediating bone erosions and cartilage damage71,72.
Our study employed a considerable RA patient cohort.
Nonetheless, there are some limitations to our study. We could
only obtain a relatively modest number of synovial fluid samples.
This was due to the fact that we only used freshly obtained
synovial fluid whose access to was seriously hindered during the
COVID-19 pandemic. Another limitation was that most of the
patients recruited presented controlled disease, which made it
difficult to correlate the frequency of TLR4+ T cells with disease
activity. In addition, our functional assays were robustly identi-
fying a causal relationship linking TLR4+ T cells selective
recognition of joint tissue environment to the type immune
profile ensued. Further studies will be needed to address the
impact of TLR4+ T cells in joint damage.
Deciphering which CD4+ T cells are relevant to the disease
process and their interplay with the joint microenvironment is a
critical hurdle to our understanding of RA. Here, we propose a
mechanism by which the joint tissue microenvironment might
reset on TLR4+ T cells pathological function. Outside the joints,
TLR4+ Tfh-like cells will be activated predominantly through the
TCR leading to the production of IL-21, which favors antibody
production and will likely contribute to anti-CCP antibody titers.
It is tempting to speculate that within the affected joints, T:T-cell
interactions mediated through non-cognate HLA-DR:TCR-cou-
pling supports TLR4 surface expression. In turn, direct sensing of
joint damage patterns by TLR4+ T cells reprograms them
towards an IL-17 pathological program that drives and sustains
cartilage damage and bone erosions. This two-prong mechanism
could highlight several attractive therapeutic targets both at the
systemic level and in the affected tissues. In addition, circulating
TLR4+ T cells in the blood could constitute a good biomarker to
predict flares and possibly which patients are more likely to
develop cartilage damage and joint erosions.
Methods
Human samples. We have complied with all relevant ethical regulations and the
Ethics Committee of NOVA Medical School (84/2019/CEFCM) and of Hospital
Egas Moniz (20170700050) approved this study. Informed consent was obtained
from RA patients that fulfilled ACR 2010 classification criteria and from HDs. RF
status, C-reactive protein level, erythrocyte sedimentation rate, and medication
usage were obtained by review of medical records. Anti-CCP antibody titers were
determined at the time of blood draw using a commercial assay anti-CCP ELISA
(IgG) from EUROIMMUN with a positive result defined as >5 RU/m. The number
of swollen and/or tender joints was measured by the attending clinician on the day
of sample acquisition. Treatments are categorized in: non-steroid anti-inflamma-
tory (NSAID), corticosteroids, disease-modifying antirheumatic drugs (DMARDs),
and biological DMARDs (dDMARDs). Blood was drawn by venipuncture into
Lithium-Heparin containing cell preparation tubes (BD, Vacutainer). Synovial fluid
was collected only when excess material was from patients undergoing diagnostic
or therapeutic arthrocentesis. For cytokine experiments, patients under biological
therapy or with combined DMARDs were not considered. One donor was excluded
owing to % TLR4 expression <0.3%. Demographic and clinical data for all the
patients enrolled in this study are listed in Supplementary Data 1 and for HDs are
listed in Supplementary Table 1.
Peripheral blood and synovial fluid cell isolation. Blood samples and synovial
fluid were processed within 4 h of collection and freshly analyzed. Peripheral blood
and synovial mononuclear cells were isolated by density gradient centrifugation
(Biocoll, Merck Millipore) or following enzymatic digestion with hyaluronidase
(10 µL mL−1; 30 min at 37 °C), respectively. Plasma and cell-depleted synovial fluid
were frozen until further use.
Antibodies and flow cytometry. For flow cytometry analysis peripheral blood
cells were stained with antibodies listed in Supplementary Data 2. For cell viability,
Fixable Viability Dye (eBioscience) or Calcein Violet-AM (Biolegend) were used.
When described, cells were cultured overnight with 10 μg mL−1 of anti-HLA-DR
antibody (L243). When mentioned FACS-purified CD14−CD3+CD4+FSClowS-
SClow cells from RA patients or CD3+CD4+ cells from HDs were stimulated with
anti-CD3 and anti-CD28 antibodies for 5/6 days and labeled for surface TLR4
expression. For proliferation assays, FACS-purified CD4+ cells from HD were
incubated in Cell TraceTM Violet dye according to the manufacturer’s instructions.
For intracellular staining, cells were treated with a Transcriptional Factor Fixation/
Permeabilization kit (ebioscience). FACS acquisition was performed in a BD
FACSCanto II instrument (BD Biosciences), BD FACSAria III (BD Biosciences),
and further analyzed with FlowJo v10.7.1 software.
Cell sorting and intracellular cytokine staining. For flow cytometry cell sorting,
cells were stained with anti-CD4 (RPA-T4) and anti-CD3 (SK7) antibodies (Bio-
Legend); anti-CD4 (RPA-T4), anti-CD3 (SK7) and anti-HLA-DR (L243) or with
anti-CD4 (SK3), anti-CD3 (UCHT1), and anti-CD14 (63D3) according to the
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sorting strategy. Gating strategies are depicted in Supplementary Figs 1–3. Sorted
populations cell purity was routinely >98%. For intracellular cytokines assays
sorted CD3highCD4high, rested for at least 3 h, were stimulated with 5 μg mL−1 of
anti-CD3 (UCHT1, BioLegend) and 2 μg mL−1 of anti-ICOS (C398.4 A, BioLe-
gend), crosslinked with 5 μg/mL anti-mouse IgG1 (BioLegend) plus 10 μg mL−1
anti-hamster IgG (Thermo Fisher Scientific) at 37°C in the presence of Brefeldin-A
(Life Technologies) for 14 h. Cells were fixed in paraformaldehyde 1% (Sigma-
Aldrich) and permeabilized with saponin (Carl Roth). Antibodies used are listed in
Supplementary Data 2. When indicated 1.7 μg mL−1 LPS (Sigma-Aldrich), TNC
(Merck Millipore), or cell-depleted synovial fluid (SF) was added. For TLR4
blocking, CLI-095 (InvivoGen) was added at 10 μg mL−1 1 h before stimulation.
Cell sorting was performed in a BD FACSAria III instrument (BD Biosciences).
Imaging, image processing, and quantification. FACS-purified CD3highCD4-
highHLA-DR+ cells from RA patients or CD3+CD4+ cells from HDs were
immediately plated onto poly-L-lysine–coated coverslips, fixed in 4% paraf-
ormaldehyde for 15 min at room temperature, incubated with blocking buffer (PBS
BSA 1%), and immunostained as previously described26,73. Antibodies used for
immunofluorescence staining are described in Supplementary Table 1. Confocal
images were obtained using a Zeiss LSM 710 confocal microscope (Carl Zeiss) over
a 63x objective. Z stack optical sections were acquired at 0.2 μm depth increments,
and both green and red laser excitation were intercalated to minimize crosstalk
between the acquired fluorescence channels. 3D image deconvolution was per-
formed using Huygens Essential 19.10, and 2D images were generated from a
maximum intensity projection over a 3D volume cut of 0.4-μm depth centered on
the cell medium plane using Imaris. For quantification of cell size and roundness,
confocal images were acquired at 2-μm increments in the z axis.
Flow cytometry data analysis. Flow cytometry data were analyzed using FlowJo
and pluggins DownSample and FlowAI. The flow cytometry data were compen-
sated at the time of acquisition with UltraComp eBeads (Thermo Fisher). As
controls unstained and FMO conditions were included. The data collected in.fcs
files were analyzed so that all abnormal events would be excluded by using
FlowAI74. Then, by using the gating strategies mentioned in the figures, dead cells
and doublets were excluded. Whenever mentioned ΔMFI was calculated by sub-
tracting the FMO from median fluorescence intensity (MFI) for any given fluor-
ophore being analyzed. t-SNE maps were generated by pooling patients and the
final n is described in the legend. Every heatmap represents differential marker
expression between TLR4+ cells (dashed gate) and remaining CD4+ T-cell
populations. To maintain the consistency of the events from each condition and
also to reduce the number of events fed into t-SNE algorithm, DownSample was
used and files were concatenated in a way that all conditions/donors could be
represented in the same plot.
Statistics and reproducibility. Statistical analysis was performed by using
GraphPad Prism v9.00 and IBM SPSS Statistics version 26 software’s. First, we
tested the normality of the data by using D’Agostino & Pearson normality test
(n > 6) or Shapiro–Wilk normality test (n ≤ 6), by checking skewness and kurtosis
values and visual inspection of data. Then, if the samples followed a normal dis-
tribution, we chose the appropriate parametric test; otherwise, the non-parametric
counterpart was chosen. We also verified the assumptions that are required for
each test. Then, by using ROUT method (Q= 1%) that is provided in GraphPad
we checked for the existence of outliers. All tests were performed with and without
outliers to verify their effect on p value and the results pointed in the same
direction (significant and non-significant values). We report here the results that
include the outliers. All statistical tests performed were two-tailed.
Overall, a p value ≤ 0.05 (α) was considered statistically significant. All the
analyses considered a 95% confidence interval. The p values were calculated using
the true distribution (exact p values). Results were considered significant at
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. For multiple comparisons,
adjusted p values were used.
In two groups comparison: for paired data, Paired t test, Ratio-paired t test or
Wilcoxon matched-pairs signed-rank test was used; for unpaired data,
Mann–Whitney test was used. For multiple groups comparison: for paired data,
Repeated measures one-way analysis of variance (ANOVA) with posttest Turkey’s
multiple comparisons or Friedman test with posttest Dunn’s multiple comparisons
was used; for unpaired data Kruskal–Wallis test with posttest Dunn’s multiple
comparisons were used as indicated. For correlations, Pearson or Spearman was
used as described. The choice of each test was dependent on the underlying
distribution and is indicated in the legend of the figures.
Data are presented as mean ± standard deviation (SD), for parametric statistical
tests and median ± interquartile range (IQR) for non-parametric statistical tests.
The number of biological replicates (n) is specified in the legend of the figure.
As a measure of the magnitude of the difference, the effect size was calculated as
described75,76:
-For Paired t test/ratio-paired t test: Cohen’s d (d) is small if <0.3; medium if
≥0.3 and <0.8 or large if ≥0.8;
-For Wilcoxon matched-pairs signed-rank test/Mann–Whitney test: correlation
coefficient r (r) is small if <0.3; medium if ≥0.3 and <0.5 or large if ≥0.5;
-For repeated measures ANOVA: partial eta-squared (ηp2) is small if ≥0.01 and
<0.06; medium if ≥0.06 and <0.14 or large if ≥0.14;
- For Friedman test: Kendall’s W (W) is small if ≥0.1 and <0.3; medium if ≥0.3
and <0.5 or large if ≥0.5;
-For Kruskal–Wallis test: eta square (η2) is small if ≥0.01 and <0.06; medium if
≥0.06 and <0.14 or large if ≥0.14;
-For Pearson correlation: Pearson’s correlation coefficient (rp): small if <0.3;
medium if ≥0.3 and <0.5 or large if ≥0.5;
-For Spearman correlation: Spearman’s correlation coefficient (rs): small if <0.3;
medium if ≥0.3 and <0.5 or large if ≥0.5.
The effect sizes values are reported in the figures and are labeled as + for
small, ++ for medium, and +++ for large effect sizes according to these values.
A table with a statistic summary per figure can be found in Supplementary
Data 3.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data sets generated during and/or analyzed during the current study are available as
Supplementary data files.
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